490 related articles for article (PubMed ID: 34771601)
1. Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma.
Kaira K; Imai H; Yamaguchi O; Mouri A; Kagamu H
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771601
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.
Arunachalam A; Zhang I; Zhao B; Frederickson AM; Catherine Pietanza M
Lung Cancer; 2023 Feb; 176():132-139. PubMed ID: 36638588
[TBL] [Abstract][Full Text] [Related]
3. Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma.
Hirai F; Seto T; Yamanaka T; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Jpn J Clin Oncol; 2013 Oct; 43(10):1018-22. PubMed ID: 23917962
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N; Umemura S; Niho S; Kirita K; Matsumoto S; Yoh K; Ohmatsu H; Goto K
Jpn J Clin Oncol; 2015 Jul; 45(7):665-9. PubMed ID: 25840444
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-based chemotherapy as second-line regimen for advanced thymic carcinoma.
Song Z; Yu X; He C; Zhang B; Zhang Y
Thorac Cancer; 2014 Mar; 5(2):169-73. PubMed ID: 26766995
[TBL] [Abstract][Full Text] [Related]
7. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.
Koizumi T; Agatsuma T; Ichiyama T; Yokoyama T; Ushiki A; Komatsu Y; Tanabe T; Kobayashi T; Yoshikawa S; Yasuo M; Yamamoto H; Kubo K; Hachiya T
Med Oncol; 2010 Jun; 27(2):392-6. PubMed ID: 19415537
[TBL] [Abstract][Full Text] [Related]
12. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
Wang Y; Zhang X; Tian D; Han S; Zhang J; Nie J; Dai L; Hu W; Chen X; Ma X; Tian G; Wu D; Zhang Z; Long J; Fang J
Cancer Med; 2023 Feb; 12(3):2303-2311. PubMed ID: 35924403
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
Wang CL; Gao LT; Lyu CX; Zhang Q; Zeng WQ; Fang WT; Zhu L; Fu XL
Med Oncol; 2022 Jan; 39(2):25. PubMed ID: 34982283
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
15. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
16. Optimal first-line treatment for advanced thymic carcinoma.
Yang X; Zhuo M; Shi A; Yang S; Wang Z; Wu M; An T; Wang Y; Li J; Zhong J; Chen H; Jia B; Dong Z; Zhao J
Thorac Cancer; 2019 Nov; 10(11):2081-2087. PubMed ID: 31574576
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Kosmas C; Tsavaris N; Kalofonos HP
Med Sci Monit; 2002 Jun; 8(6):PI58-63. PubMed ID: 12070450
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.
Okuma Y; Hosomi Y; Watanabe K; Takahashi S; Okamura T; Hishima T
Int J Clin Oncol; 2016 Jun; 21(3):531-8. PubMed ID: 26646221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
